Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Getsios

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neurology|September 26, 2001
Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in CanadaD Getsios, J J Caro, G Caro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 14, 2001
Diabetes in Canada: direct medical costs of major macrovascular complicationsJ A O'Brien, I Caro, D Getsios, et al.
Headache|May 31, 2001
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysisJ J Caro, D Getsios, G Raggio, et al.
Neurology|September 26, 2001
Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time careJ J Caro, D Getsios, K Migliaccio-Walle, et al.
International Journal of Geriatric Psychiatry|August 2, 2003
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UKA Ward, J J Caro, D Getsios, et al.
Headache|April 12, 2000
The migraine ACE model: evaluating the impact on time lost and medical resource UseJ J Caro, G Caro, D Getsios, et al.
Cephalalgia : an International Journal of Headache|April 12, 2001
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysisG Caro, D Getsios, J J Caro, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 23, 2004
Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in CanadaJ J Caro, D Getsios, I Caro, et al.
Clinical Drug Investigation|May 23, 2007
Oxybutynin extended release and tolterodine immediate release : a health economic comparisonD Getsios, J J Caro, K J Ishak, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neurology|September 26, 2001
Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in CanadaD Getsios, J J Caro, G Caro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 14, 2001
Diabetes in Canada: direct medical costs of major macrovascular complicationsJ A O'Brien, I Caro, D Getsios, et al.
Headache|May 31, 2001
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysisJ J Caro, D Getsios, G Raggio, et al.
Neurology|September 26, 2001
Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time careJ J Caro, D Getsios, K Migliaccio-Walle, et al.
International Journal of Geriatric Psychiatry|August 2, 2003
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UKA Ward, J J Caro, D Getsios, et al.
Headache|April 12, 2000
The migraine ACE model: evaluating the impact on time lost and medical resource UseJ J Caro, G Caro, D Getsios, et al.
Cephalalgia : an International Journal of Headache|April 12, 2001
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysisG Caro, D Getsios, J J Caro, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 23, 2004
Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in CanadaJ J Caro, D Getsios, I Caro, et al.
Clinical Drug Investigation|May 23, 2007
Oxybutynin extended release and tolterodine immediate release : a health economic comparisonD Getsios, J J Caro, K J Ishak, et al.
Pageof 1